A compound that mimics the structure of genetic material present in some viruses improved the efficacy of existing immunotherapies in mouse models of human melanoma, according to a study in Science Translational Medicine. The compound, which is now in human trials, makes tumor cells that have stopped producing antigens recognizable to the immune system.
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.